Activity Assay Kits

Z-Glutamyl(γ-hydroxamate)-glycine



Order
Quantity
Price
Status
100 mg 125 € available


Documents
Art. No. Z018
Synonym Z-Glu(γ-hydroxamate)-Gly-OH
Background info The standard hydroxamate assay uses Z-Gln-Gly-OH as peptidic glutamine substrate and hydroxylamine as amine donor. In the presence of MTG, hydroxylamine is enzymatically incorporated into the peptide to form Z-Glutamyl(γ-hydroxamate)-glycine. The hydroxamate forms a red colored complex with iron (III) ions quantified at 525 nm.
One unit of microbial transglutaminase activity is defined as the amount of enzyme, which causes the formation of 1.0 μmole of hydroxamate per minute at 37ºC (Folk and Cole, 1966).
Z018 represents the reaction product to be measured by the chromogenic endpoint assay, allowing the determination of a calibration curve. For each setting, molar attenuation coefficient (ε) needs to be determined individually.
We recommend using Z018 to replace G048, which represents the glutamyl(γ-hydroxamate) as a surrogate only.
Molecular Formula C15H19N3O7
Molecular Weight 353.33
Appearance White solid
Solubility >50 mM in aqueous buffers
Dissolve e.g. 10 mg (28.3 μmol) of Z018 in 566 μL of aqueous buffer to obtain a 50 mM (17.7 mg/mL) stock solution.
Application Reference substance to determine the concentration of product formed by microbial transglutaminase (MTG).
Storage Store at -20°C, desiccate
Note INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification

Blog  

  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events  

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy